Imagion Biosystems has successfully placed AU$3 million

Imagion Biosystems (ASX: IBX) announced that it had secured a significant AU$3 million in firm commitments through a highly successful capital raising. These funds will be instrumental in accelerating its priority work programs and clinical studies on its groundbreaking MagSense platform technology. The lead program has already shown promising results, demonstrating the safety and tolerability of its innovative MagSense HER2 Imaging Agent in patients with HER2+ breast cancer.

This significant capital infusion will propel the company's mission to revolutionize cancer detection and treatment. The company is immensely grateful for the support and commitment of its investors. It is excited about the transformative impact of its MagSense technology, which has the potential to significantly improve cancer diagnosis and treatmen

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com